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Summary In about 50% of patients with stage IV neuroblastoma, micrometastases are present in the bone
marrow when it is harvested for an autograft to follow induction therapy, and the risk of graft contamination
by neuroblastoma cells has been the rationale for the use of a purging procedure. However, bone marrow
metastases are detected with trephine biopsies which only explore the sites biopsied and do not reflect
potential contamination of the pooled marrow harvested for autograft. A two-colour fluorochrome labelling
method is described which permits as few as 1 neuroblastoma cell in 100,000 normal bone marrow cells from
the autograft to be detected. Three monoclonal antibodies (UJ13A, HIl and 11.14) which react with
neuroblastoma cells are used as single reagent in combination with a fourth anti-panleucocyte antibody. This
method requires only 2h for the analysis of three million marrow cells from the autograft, and is more
effective than alkaline phosphatase staining with the same monoclonal antibodies. Results were compared
with conventional techniques (four biopsies and four aspirates) carried out at the same time in 34 consecutive
patients. Of 18 cases with negative aspirates and biopsies, neuroblastoma cells were detected in two autografts
by the immunological method. Of 16 cases with positive aspirates and/or biopsies, 10 autografts were positive
by the immunological method and six were negative. Thus, marrow micrometastases were detected in 16 of
the 34 patients, but the autograft contained malignant cells in only 12 of these patients and the
immunological analysis demonstrated that the use of a purging procedure allowed the elimination of
neuroblastoma cells from the autograft before its reinjection to the patients.
Intensive chemotherapy followed by autologous bone
marrow transplantation (ABMT) is now widely used as early
consolidation therapy for stage IV neuroblastoma in children
over one year of age (August et al., 1984; Philip et al., 1987;
Graham-Pole et al., 1984; Pritchard et al., 1982; Hartmann
et al., 1987; D'Angio et al., 1985). After induction therapy,
at least 50% of such children fail to achieve complete
remission and receive their bone marrow graft in partial
remission. In these patients, scanty neuroblastoma cells may
be detected in the marrow by the analysis of multiple
biopsies although aspirates were often negative (Favrot et
al., 1986; Favrot & Herve, 1987; Franklin & Pritchard, 1983;
Borstrom et al., 1985); this may be due to lack of sensitivity
of cytological detection methods or to the fact that these
clumps of neuroblastoma cells are not sucked out. One of
the major issues in the treatment of neuroblastoma is thus to
know whether bone marrow harvested for an autograft
contains malignant cells or not, and whether these cells can
be eliminated by an in vitro purging procedure before the
graft is reinjected. It is therefore of major importance to
develop accurate methods to detect and quantify rare
neuroblasts in the marrow to be used for autograft.
Neuroblasts have very low clonogenic efficiency in culture,
however; cytogenetic analysis is not useful in detecting very
small numbers of neuroblasts, and molecular biology
techniques do not yet permit detection of less than 2%
malignant cells (Favrot & Herve, 1987). In theory,
immunological analysis should be the optimal method of
detection since monoclonal antibodies which recognise
neuroblasts are now available (Allan et al., 1983; Kemshead
et al., 1983; Combaret et al., 1988; Favrot et al., 1988;
Cheung et al., 1986; Evans et al., 1984). In practice,
however, there remain technical problems due to the fact
that anti-neuroblastoma MoAbs may stain a few normal
marrow cells non-specifically, especially when the marrow is
analysed after a course of chemotherapy. Immuno-
cytochemical methods (e.g. alkaline phosphatase or
peroxidase immunostaining) preserve the cytological features
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of the cells and allow positively stained normal cells to be
distinguished from malignant cells, but the method is time-
consuming and the number of cells that can be analysed is
limited. In this paper we describe a simple and brief method
of two-colour fluorochrome labelling in which three
monoclonal antibodies (UJ13A, H11 and 11.14) reacting
with neuroblasts are used as single reagent in combination
with an anti-panleucocyte antibody directed against normal
marrow cells. This double marker analysis allows detection
of as few as 10-5 malignant cells in the normal marrow. In
this study and for 34 patients, the BM harvested for an
autograft has been analysed with the immunological method
and the results have been compared to those of the
cytohistological analysis of four trephine biopsies and four
aspirates. The same method has been used to demonstrate
the elimination of the detectable residual malignant cells by
the purging procedure.
Materials and methods
Patients and materials
Subjects were either unselected stage IV neuroblastoma
patients over one year of age, treated in consolidation by our
current LMCE (Lyon, Marseille, Curie, East of France
Cooperative Group) protocol of high dose chemotherapy
and ABMT (Philip et al., 1987a,b), or patients referred from
other centres for inclusion in the Centre Leon Berard pilot
study of double ABMT (Philip et al., 1988). In the first
group marrow was harvested after four to seven courses of
induction therapy as previously described (Philip et al.,
1987a). In the second group, patients usually received two
courses of VP16 and CDDP before marrow harvesting
(Philip et al., 1987b, 1988).
Morphological examination of the marrow was performed
as previously described (Favrot et al., 1986). At the time of
marrow harvesting under general anaesthesia, four marrow
biopsies and four aspirates were performed in posterior and
anterior iliac crests. Formalin-fixed trephines were analysed
with conventional haematein phloxin safran staining; two
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spread films from each marrow aspirate were stained by
May Grumwald Giemsa.
Harvested marrow was collected on citrate phosphate
dextrose; mononuclear marrow cells were obtained by Ficoll
separation on a blood cell processor (COBE 2991). Five
million mononuclear marrow cells were taken for
immunological analysis before purging, and the harvested
marrow was then purged by an immunomagnetic depletion
(IMD) procedure using five monoclonal antibodies (i.e.
UJ13A, H-1, UJ127-11, UJ181-4 and aThy 1), as previously
described (Favrot et al., 1987; Combaret et al., 1988;
Trealeaven et al., 1984). A further five million mononuclear
marrow cells were then taken for immunological analysis
after purging.
Normal bone marrow samples
After informed consent, according to the Centre Leon
Berard ethical rules, marrow samples obtained under general
anaesthesia from non-cancer patients or regenerating marrow
samples from patients with neuroblastoma or malignant
lymphoma in complete remission were used as control for
the immunological analysis (see below).
Immunological analysis
UJ13A and HI1 MoAbs (kindly provided by J. Kemshead)
and S-L 11.14 (kindly provided by J.C. Laurent) recognise
antigens expressed by cells of neuroectodermal origin (11-
14). These IgG antibodies strongly react with 90% of our
patients' tumour samples (either neuroblastoma cells in
heavily involved marrow, at diagnosis or relapse, or primary
tumours taken at surgery). The UJ13A and Hi 1 MoAbs are
included in the cocktail used for the purging procedure
whereas 11.14 was selected in such study as a third marker
which does not interfere with the purging cocktail. NKHia
(Coulter, France) is an IgM reagent claimed to be relatively
specific for NK cells (Hercend et al., 1983). An IgM anti-
panleucocyte MoAb (recognising CD45) was kindly provided
by G. Janossy.
Two-colour fluorochrome immunostaining Three samples
(1 x 106 marrow cells per sample, in suspension in 100II
phosphate buffer saline (PBS) with 0.1% NaNa3) are
incubated with the three anti-neuroblastoma monoclonal
antibodies (one for each sample) in combination with either
the anti-panleucocyte or NKHIa. After 10min at 24°C,
samples are washed once in PBS and incubated with TRITC
anti-mouse IgM specific and FITC anti-mouse IgG specific
(Southern Biotechnology Associates, ref. 1020 and 1030) for
10min at 24°C (specificity of the class-specific antisera has
previously been checked on monoclonal antibodies of
different subclasses). Samples are then washed twice,
maintained in PBS-glycerol and analysed in a fluorescent
Zeiss microscope with a 40:1 objective, a 490nm excitation
filter and a K530 barrier filter. Negative controls include one
sample stained with the two second layers without
monoclonal antibody.
Alkaline phosphatase immunostaining Marrow cells in
suspension at 6 x I0 ml - in PBS were cytocentrifuged into
glass (1001M per smear at 70g for 5min in a Shandon
cytospin) (Warnke et al., 1983; Maritaz et al., 1988).
Immunochemical staining is performed using an indirect
three-stage immunoenzymatic procedure (20, 21) with
alkaline phosphatase (Dakopatts, Copenhagen, Denmark).
Briefly, six air-dried slides are fixed for 5min with acetone at
40C, incubated for 60min with MoAbs (three with UJ13A
and three with 11.14) then for 30min with enzyme-
conjugated rabbit anti-mouse immunoglobulins (Dakopatts)
and for 30min with enzyme-conjugated swine anti-rabbit
immunoglobulins (Dakopatts). Washes are done with Tris
buffer. The final step consists of a 15-min incubation with
Naphtol-As-Mx phosphate, dimethylformamide, levamisole
and fast red (Sigma Co., St Louis, USA). Slides are
counterstained with haematoxylin, mounted permanently
with glycerin and evaluated under an optical microscope.
Negative controls without monoclonal antibody and positive
controls with MoAbs recognising class I antigen on normal
marrow cells are included in each test. Slides were considered
technically unsatisfactory and were not evaluated if any of
the following was observed: (I) positive staining in the
negative control; (2) high background staining in the test
samples; (3) disrupted morphology with absence of
recognisable cellular structures.
Limit of detection The methods were shown to enable the
detection of as few as 10-5 neuroblastoma cells in the
marrow if 3 x 106 cells are analysed in two-colour
fluorochrome labelling and six smears in alkaline
phosphatase (blind study) (Maritaz et al., 1988).
Results
Reactivity of 11.14, UJ13A and Hi1 with normal
haematopoietic cells
Ten marrow samples from healthy donors were analysed by
the two-colour fluorochrome labelling; all three MoAbs,
used as single reagent, stained less than 1% haematopoietic
cells. In patients treated for malignant lymphoma and in
complete remission, samples of regenerating marrow taken
after chemotherapy contained up to 10% marrow cells stained
with one or the other reagent. Such non-specific staining was
also observed in our neuroblastoma patients in complete
remission. Two-colour fluorochrome labelling with an anti-
panleucocyte monoclonal antibody on normal marrow or
marrow from patients with malignant lymphoma in
remission enabled us to confirm that these positive isolated
cells were indeed of haematopoietic origin. Similarly, double
labelling with NKH1, on those samples proved that those
rare lymphoid cells reacting with anti-NBL markers
belonged to the natural killer cell subpopulation. In the
results described below, all samples were analysed by two-
colour fluorochrome labelling.
Comparison of the morphological detection of bone marrow
micrometastasis with the immunological detection of
malignant cells in the autograft: 34 cases
Samples for morphological analysis of the marrow and
immunological analysis of the autograft were taken on the
same day during the marrow harvest surgical procedure.
Four biopsies and eight spread films (two per aspiration site)
were analysed for each patient. Three million cells were
analysed in two-colour fluorochrome labelling and six
smears (6 x 104 cells per smear) were analysed by alkaline
phosphatase immunostaining before and after the purging
procedure. (see Table I).
In 16 cases, both morphological examination of the
marrow and immunological analysis of harvested marrow
cells were normal. In 18 cases, malignant cells were detected
in the marrow by one or the other method as detailed below.
In three cases, biopsies, aspirates and immunological
analysis were positive; two to three of the eight morpho-
logical specimens contained one or two clumps of neuroblas-
toma cells and the immunological analysis permitted to
detect from 10-4 to 1% residual malignant cells in the three
corresponding autografts before purging.
In 12 cases, biopsies were positive but aspirates were
negative; three patients had only one positive biopsy but
three patients had three to four positive biopsies with one or
two detectable clumps in each. Before the purging procedure,
the immunological analysis permitted to detect 10-3 to 10-5
residual neuroblastoma cells in the autograft of only six of
these patients.
In one case, the four biopsies were negative but the
aspirates contained rare atypical lymphoid-like malignant846 V. COMBARET et al.
Table I Comparison of morphological and immunological methods for detection of neuroblastoma cells
in the bone marrow
BM Micrometastasis Neuroblastoma cells
Before the purging procedure After the purging procedure
Alkaline Two-colour fluoro- Alkaline Two-colour fluoro-
Biopsies(4) Aspirations(4) phosphatase chrome labelling phosphatase chrome labelling
-(16 cases) - -(16 cases)
+ +(3 cases) + -(1 case)
+ +(2 cases)a
+ -(12 cases) - -(6 cases)
+ +(I case)
- +(4 cases)
+ -(1 case)
- +(I case) + +(I case)
- -(2 cases) - +(2 cases)
aIn one of the two patients, one biopsy and one aspiration were positive in anterior iliac crests, as was
the marrow harvested in anterior crests. Biopsies, aspirates and immunological analyses were negative in
posterior iliac crests; bone marrow was then harvested in posterior iliac crests and shown to be free from
malignant cells.
cells; the immunological analysis of the autograft confirmed
the presence of 1% malignant cells.
In two cases the four biopsies and four aspirates were
completely negative, but clumps of malignant cells were
detected in the autograft by the two-colour fluorochrome
labelling, the contamination being 1 NBL cell in 105 marrow
cells.
Finally, when marrows were analysed after the purging
procedure they did not contain any residual neuroblastoma
cell detectable by immunological analysis.
The combination of these two immunological methods
enables detection of one NBL cell in 105 marrow cells in the
autograft. Particularly in 11 of the 12 cases of contaminated
autografts, malignant cells were detectable by the two-colour
fluorochrome labelling; alkaline phosphatase immunostaining
was positive in only five cases, one only with negative
immunofluorescence and four with concomitant positive
immunofluorescence.
Discussion
In this series of 34 consecutive neuroblastoma patients
entered in an AMBT programme, 16 had marrow micro-
metastases detectable by cytohistological examination of four
trephine biopsies and four aspirates on the day of marrow
harvest; in agreement with our previous results, biopsies were
more accurate than aspirates in detecting these rare neuro-
blasts. The marrow infiltration by neuroblastoma cells is
very focal and biopsies or aspirates only explore four iliac
sites whereas the marrow harvested for an autograft is taken
from the entire iliac site. The immunological analysis of the
cells from the whole harvested marrow enabled us to demon-
strate that the autograft was contaminated by neuroblasts in
12 of the 34 cases analysed, 10 with concomitant positive
biopsies and/or aspirates, and two with negative biopsies and
aspirates. The autograft contamination could be quantified
and ranged from 10-2 to 10-5 malignant cells; after ex vivo
purging procedure, none of the autografts contained residual
malignant cells detectable by immunological analysis; less
than 10-5 neuroblasts were thus potentially left when the
marrow was reinjected to the patient. In the seven cases in
which one of the biopsies was positive and malignant cells
were undetectable in the harvested marrow by immunologi-
cal analysis, the autograft contained less than 10-5 NBL
cells or could even be normal if very focal clumps of
malignant cells failed to be aspirated during the harvesting
procedure.
The great sensitivity of the immunological detection is
due, first, to the Ficoll separation of the mononuclear cell
population before the analysis. Separation of the marrow
cells, either on a Ficoll gradient or on a discontinuous
sedimentation gradient, had been reported to enrich the
marrow population with malignant cells, by eliminating red
cells and granulocytes, and to improve the examination
(Maritaz et al., 1988; Bayle et al., 1985; Hunter et al., 1987).
The sensitivity of the method described here is due, secondly,
to the objective characterisation of malignant cells. The two-
colour fluorochrome labelling method enables an objective
distinction to be made between the few lymphocytes which
stain with both the anti-panleucocyte and the anti-
neuroblastoma antibodies, and isolated neuroblastoma cells
which are panleucocyte negative. Similarly, the immunoalka-
line phosphatase staining permits identification of pseudo-
lymphoid neuroblasts by their membrane positivity. Finally,
the number of cells analysed for each case in this study
(3 x 106 in two-colour fluorochrome labelling and 6 x 105 in
alkaline phosphatase) allows detection down to 10-5 neuro-
blasts by immunological analysis. In this context, two-colour
fluorochrome labelling offers several advantages when com-
pared to alkaline phosphatase staining. In the first method,
the processing of 3 x 106 mononuclear cells only requires
90 min once the marrow has been harvested and their
analysis on three different slides takes 30min. Immunostain-
ing and analysis of six smears by the alkaline phosphatase
method usually takes 4-5 h and consequently limits the total
number of mononuclear cells to be analysed. The greater
sensitivity of two-colour fluorochrome labelling is due to the
larger number of cells analysed. Two-colour fluorochrome
labelling thus appears, both for its sensitivity and its simpli-
city, as an optimal method to develop routinely in a
laboratory involved in clinical programmes in ABMT. The
method can be easily adjusted to the analysis of the marrow
in various solid tumours. In small cell lung cancer, the three
markers used in this study (UJ13A, Hi 1 and 11.14) strongly
react with the malignant cells and the method of detection is
strictly similar; in other tumours such as breast cancer,
relevant markers of the malignant cells are available.
For clinicians, such an analysis clearly selects a group of
patients whose autograft is contaminated with malignant
cells and for whom the use of a purging procedure is largely
justified. In addition, the immunological analysis enables the
efficiency of clinical purging procedures to be checked and
allows the elimination of malignant cells to be quantified.
Such data are of particular interest in a disease such as
neuroblastoma in which two patients out of three never
reach complete remission and are thus autografted in partial
remission. To determine whether relapses are due to the
failure of high dose chemotherapy or to the reinjection of
malignant cells is a prerequisite in the improvement or
modification of therapeutic protocols.
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